MVZ II der Niels Stelsen Kliniken
- Address
- Alte Rothenfelder Straße 23, 49124 Georgsmarienhütte, Germany
MVZ II der Niels Stensen Kliniken - Oncology Research Center
MVZ II der Niels Stensen Kliniken is a specialized medical research center with expertise in advanced cancer therapeutics, particularly focusing on precision oncology and targeted therapy approaches. The center demonstrates particular strength in investigating novel treatment strategies for patients with genetically defined lung cancer subtypes.
- ALK-positive non-small cell lung cancer (ALK+ NSCLC) research
- Second-generation tyrosine kinase inhibitor (TKI) comparative studies
- Deep phenotyping and precision medicine approaches in oncology
The center's research program emphasizes evaluating brigatinib and other targeted therapies in patients with locally advanced or metastatic ALK+ NSCLC. Their work includes rigorous assessment of treatment efficacy using standardized criteria such as RECIST v1.1, with a focus on progression-free survival outcomes and comparative effectiveness of first-line versus second-generation TKI therapies in molecularly selected patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MVZ II der Niels Stelsen Kliniken
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy Comparison of Brigatinib Versus Second-Generation TKIs in First-Line Treatment of Locally Advanced or Metastatic ALK-Positive NSCLC | Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH | Phase II | Not Recruiting | Mar 2020 | May 2026 |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Alectinib | 1 | Unknown | 2020-03-30 | 2020-03-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.